AMA hops on the social media bandwagon

Share this article:
AMA hops on the social media bandwagon
AMA hops on the social media bandwagon
In just over a month, the American Medical Association has launched a YouTube channel, a blog written by AMA president James Rohack and a Facebook page.

AMA kicked off its YouTube presence with a video emphasizing the need for healthcare reform, and has since launched three “virtual town hall” videos tackling various aspects of the healthcare reform debate. AMA was an early supporter of the House bill on health reform, and has faced a backlash from some quarters of the medical community as a result.

Physician online community Sermo and the AMA ended their partnership in July after disagreements over the terms of their relationship.  On September 8, AMA announced the launch of a presence on Facebook. Rohack said in a release that the AMA's Facebook page “is a tool for patients and physicians to learn and communicate with each other about the latest health-reform developments.” The Facebook page, which links to the YouTube channel and offers other information, photos and links, currently has 705 “fans.”

Rohack's blog, titled On the Road with Dr. Rohack, launched in late August and is focused on chronicling his travels across the country as an AMA advocate. In his inaugural post, Rohack reiterated the AMA's stance on health reform, and encouraged doctors and their patients to visit the AMA's health system reform site.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...